Anita Treohan

Corporate Officer/Principal presso AVROBIO, INC.

Consumer Services

Health Technology

Profilo

Anita Treohan is currently working as the VP-Clinical Development Operations at Avrobio, Inc. Previously, she worked as the Director-Clinical Operations at ImmusanT, Inc. She completed her graduate degree at Boston University and her undergraduate degree at Emory University.

Posizioni attive di Anita Treohan

Società	Posizione	Inizio
AVROBIO, INC.	Corporate Officer/Principal	-

Tutte le posizioni attive di Anita Treohan

Precedenti posizioni note di Anita Treohan

Società	Posizione	Fine
ImmusanT, Inc. ImmusanT, Inc. Medical SpecialtiesHealth Technology ImmusanT, Inc. develops a new class of therapeutic vaccines to change the lives of people living with autoimmune diseases. Its Epitope-Specific Immuno-Therapy platform provides a precision medicine approach to restoring immune tolerance across a range of diseases, including celiac disease and type 1 diabetes. The firm’s product Nexvax2, protects celiac disease patients against the debilitating effects of gluten. The company was by Leslie J. Williams and Robert P. Anderson founded in December 2010 and is headquartered in Cambridge, MA.	Corporate Officer/Principal	-

Vedi nel dettaglio l'esperienza di Anita Treohan

Formazione di Anita Treohan

Boston University	Graduate Degree
Emory University	Undergraduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Anita Treohan

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
AVROBIO, INC.	Health Technology

Aziende private	1
ImmusanT, Inc. ImmusanT, Inc. Medical SpecialtiesHealth Technology ImmusanT, Inc. develops a new class of therapeutic vaccines to change the lives of people living with autoimmune diseases. Its Epitope-Specific Immuno-Therapy platform provides a precision medicine approach to restoring immune tolerance across a range of diseases, including celiac disease and type 1 diabetes. The firm’s product Nexvax2, protects celiac disease patients against the debilitating effects of gluten. The company was by Leslie J. Williams and Robert P. Anderson founded in December 2010 and is headquartered in Cambridge, MA.	Health Technology